Suvorexant to Reduce Symptoms of Nicotine Use

Phase 2 Completed 14 enrolled The University of Texas Health Science Center, Houston

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the impact of suvorexant on established measures of smoking relapse risk (craving,withdrawal, stress reactivity, latency to self-administration) and to validate the somnolent effect of suvorexant on sleep metrics in a sample of individuals with tobacco use disorder

Timeline

Start: 2021-08-23
Primary completion: 2024-08-22
Completion: 2024-08-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Suvorexant	Small molecule	20 mg	—

Indications

No indication recorded.